Cover Image
市場調查報告書

口腔粘膜炎 : 開發中產品分析

Oral Mucositis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192750
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
口腔粘膜炎 : 開發中產品分析 Oral Mucositis - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 90 Pages
簡介

口腔黏膜炎是最常見的黏膜炎之一,是在癌症外手術、化療、放射線療法時經常併發的衰弱性疾病。主要的症狀有口腔內部色調異常或唾液分泌減少、黏膜構造發生變化、唇、舌浮腫等。主要治療方法有清潔口腔(口腔衛生)、口腔內部的清創手術等。

本報告提供全球各國治療口腔粘膜炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

口腔粘膜炎概要

治療藥的開發

  • 口腔粘膜炎開發中產品:概要
  • 口腔粘膜炎開發中產品:比較分析

各企業開發中的口腔粘膜炎治療藥

大學/研究機關研究中的口腔粘膜炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

口腔粘膜炎治療藥:開發中的產品一覽(各企業)

口腔粘膜炎治療藥:研究中的產品一覽(各大學/研究機關)

口腔粘膜炎開發治療藥的企業

  • Aldeyra Therapeutics, Inc.
  • Cellceutix Corporation
  • Colby Pharmaceutical Company
  • Daewoong Pharmaceutical Co., Ltd.
  • Galera Therapeutics, Inc.
  • Onxeo SA
  • Oragenics, Inc.
  • 大塚集團
  • Soligenix, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Spherium Biomed S.L.

口腔粘膜炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

口腔粘膜炎治療藥:暫停開發的產品

口腔粘膜炎治療藥:中止開發的產品

口腔粘膜炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8372IDB

Summary

Global Markets Direct's, 'Oral Mucositis - Pipeline Review, H2 2016', provides an overview of the Oral Mucositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Oral Mucositis
  • The report reviews pipeline therapeutics for Oral Mucositis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Oral Mucositis therapeutics and enlists all their major and minor projects
  • The report assesses Oral Mucositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Oral Mucositis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Oral Mucositis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oral Mucositis Overview
  • Therapeutics Development
    • Pipeline Products for Oral Mucositis - Overview
    • Pipeline Products for Oral Mucositis - Comparative Analysis
  • Oral Mucositis - Therapeutics under Development by Companies
  • Oral Mucositis - Therapeutics under Investigation by Universities/Institutes
  • Oral Mucositis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Oral Mucositis - Products under Development by Companies
  • Oral Mucositis - Products under Investigation by Universities/Institutes
  • Oral Mucositis - Companies Involved in Therapeutics Development
    • Aldeyra Therapeutics, Inc.
    • Cellceutix Corporation
    • Colby Pharmaceutical Company
    • Daewoong Pharmaceutical Co., Ltd.
    • Galera Therapeutics, Inc.
    • Onxeo SA
    • Oragenics, Inc.
    • Otsuka Holdings Co., Ltd.
    • Soligenix, Inc.
    • Spectrum Pharmaceuticals, Inc.
    • Spherium Biomed S.L.
  • Oral Mucositis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AG-013 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clonidine hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-4419 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Oral Mucositis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-219 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nepidermin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pralatrexate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rebamipide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-13004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Oral Mucositis - Dormant Projects
  • Oral Mucositis - Discontinued Products
  • Oral Mucositis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
      • Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
      • Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
      • May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
      • Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
      • Jan 07, 2016: Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis
      • Dec 21, 2015: SciClone To Pursue Development Of SGX942 In China Following Soligenix' Report Of Positive Phase 2 Preliminary Results In Oral Mucositis
      • Dec 16, 2015: Soligenix Announces Positive Preliminary Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Dec 04, 2015: Soligenix Provides Clinical Program Updates on SGX942 for December 2015
      • Nov 25, 2015: FDA Grants Fast Track Designation to Cellceutix's Brilacidin-OM for Oral Mucositis
      • Oct 22, 2015: Onxeo Announces Data Demonstrating High Patient Compliance and Acceptability of Validive for Treatment of Severe Oral Mucositis
      • Oct 19, 2015: Onxeo Validive Abstract Accepted for Oral Presentation at ASTRO Annual Meeting 2015
      • Sep 09, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Succinic Semi-Aldehyde Dehydrogenase Deficiency at the 2015 American Society of Human Genetics Annual Meeting
      • Aug 31, 2015: Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
      • Aug 03, 2015: Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Oral Mucositis, H2 2016
  • Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Oral Mucositis - Pipeline by Aldeyra Therapeutics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Cellceutix Corporation, H2 2016
  • Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Oral Mucositis - Pipeline by Galera Therapeutics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Onxeo SA, H2 2016
  • Oral Mucositis - Pipeline by Oragenics, Inc., H2 2016
  • Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Oral Mucositis - Pipeline by Soligenix, Inc., H2 2016
  • Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
  • Oral Mucositis - Pipeline by Spherium Biomed S.L., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Oral Mucositis - Dormant Projects, H2 2016
  • Oral Mucositis - Dormant Projects (Contd..1), H2 2016
  • Oral Mucositis - Dormant Projects (Contd..2), H2 2016
  • Oral Mucositis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Oral Mucositis, H2 2016
  • Number of Products under Development for Oral Mucositis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top